Prosecution Insights
Last updated: November 13, 2026
Application No. 18/688,756

Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA)

Non-Final OA §102§103§112
Filed
Mar 02, 2024
Priority
Sep 03, 2021 — EU 21194940.9 +1 more
Examiner
SALVOZA, M FRANCO G
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bavarian Nordic A/S
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
428 granted / 629 resolved
+8.0% vs TC avg
Strong +31% interview lift
Without
With
+30.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
64 currently pending
Career history
685
Total Applications
across all art units

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election Restrictions 1. Applicant’s election without traverse of Group I and species (SEQ ID NO: 1; SEQ ID NO: 54; RSV N/M2-1 fusion protein; CEF cells; PrLE1 promoter) in the reply filed on 7/20/2026 is acknowledged. Claims 10-12, 15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 7/20/2026. Claims 1-9, 13 are under consideration. Priority 2. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement 3. The information disclosure statement (IDS) was submitted on 3/2/2024; 7/20/2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Drawings 4. The drawings were received on 5/17/2024. The drawings are objected to because the labels should read “FIG.” instead of “FIGURE” (See MPEP 1825). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 1-9, 13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. See claims 1-9, 13 as submitted 7/20/2026. As to claims 1-3, it is not clear what the metes and bounds of “miRblock” are, or what distinguishes a block from a sequence of nucleotides. Claims 4-9, 13 depend on these claims. Further as to claims 4, 7, 8, 9, the claims recite “preferably”. It is not clear if the subsequent language is a limitation or not. Further as to claim 4, it is not clear what “the miRNA” refers to. Claim Rejections - 35 USC § 102/103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 6. Claims 1-4, 8, 13 are rejected under 35 U.S.C. 102(a)(1)/102(a)(2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Robinson et al. (US20130280215)(cited in applicant's IDS submitted 3/2/2024). See claims 1-4, 8, 13 as submitted 7/20/2026. See also the 35 U.S.C. 112(b) rejection above. Robinson et al. teaches: vectors capable of expressing polypeptides in cells (abstract); compositions containing them (abstract); including: recombinant MVA vector [0004](as recited in claims 1, 13); sequence that encodes foreign polypeptide (transgene) [0040](as recited in claims 1, 2, 3); vaccine inserts [0002]; poxvirus promoter (claim 13 of Robinson et al.)(as recited in claim 1, 2); one or more miRNA target sequences [0005](as recited in claims 1, 2, 3); including miRNA target sequences that suppress expression in a cell type [0004](as recited in claims 1, 2, 3, 4); wherein miRNA target sequences are selected to repress expression at the translational levels in the cell line used for production of the MVA while not doing so in certain human cells [0005]; CEF cell [0008](as recited in claim 8). Thus, in view of the foregoing, all the claimed limitations are found in one reference and are taught to be optional variations to a ‘base’ product they exemplify. As such, the claimed sequences are within the scope of Robinson et al., and thus Robinson et al. renders the product comprising sequences prima facie obvious. The rationale to support this conclusion of obviousness is that Robinson et al. provides a teaching, suggestion, and motivation to substitute different variables disclosed within the reference. Furthermore, there is no evidence on the record that indicates that the claimed supplement exhibits any unexpected results compared to the prior art. Thus, Robinson et al. anticipates or renders obvious the instant claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 7. Claim 7 is rejected under 35 U.S.C. 103 as being unpatentable over Robinson et al. as applied to claims 1-4, 8, 13 above, and further in view of Lutz et al. (US20210170017A1)(See PTO-892: Notice of References Cited) See claim 7 as submitted 7/20/2026. See the teachings of Robinson et al. above. Robinson et al. does not teach: RSV N/M2-1 fusion protein. Lutz et al. teaches: vaccine compositions (abstract); nucleic acids such as DNA, RNA or hybrid [0034]; coding sequences encoding at least one antigenic peptide [0085]; constructs to induce immune response, including for N and M2-1 [0968]; sequence comprising at least one sequence derived from N, M2-1 [0443; claim 30 of Robinson et al.](interpreted to read upon fusion constructs).. One of ordinary skill in the art would have been motivated to use sequence as taught by Lutz et al. with the composition as taught by Robinson et al. Robinson et al. teaches use of vaccine inserts and transgene or sequence that encodes foreign polypeptide, and Lutz et al., which also teaches vaccine compositions, teaches such a sequence (See MPEP 2144.06: Substituting equivalents known for the same purpose). One of ordinary skill in the art would have had a reasonable expectation of success for using sequence as taught by Lutz et al. with the composition as taught by Robinson et al. There would have been a reasonable expectation of success given the underlying materials (expression constructs as taught by Robinson et al. and Lutz et al.) and methods are known, successfully demonstrated, and commonly used as evidenced by the applied prior art. Therefore the invention as a whole would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. 8. Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Robinson et al. as applied to claims 1-4, 8, 13 above, and further in view of Kalla et al. (US20200061174A1)(See PTO-892: Notice of References Cited) See claim 9 as submitted 7/20/2026. See the teachings of Robinson et al. above. Robinson et al. does not teach: PrLE1 promoter. Kalla et al. teaches: recombinant poxvirus (abstract); use of PrLE1 promoter [0113]. One of ordinary skill in the art would have been motivated to use promoter as taught by Kalla et al. with the composition as taught by Robinson et al. Robinson et al. teaches use of poxvirus promoter, and Kalla et al., which also teaches poxvirus promoter, teaches such a known promoter (See MPEP 2144.06: Substituting equivalents known for the same purpose). One of ordinary skill in the art would have had a reasonable expectation of success for using promoter as taught by Kalla et al. with the composition as taught by Robinson et al. There would have been a reasonable expectation of success given the underlying materials (poxvirus promoter as taught by Kalla et al. and Robinson et al.) and methods are known, successfully demonstrated, and commonly used as evidenced by the applied prior art. Therefore the invention as a whole would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. Conclusion 9. SEQ ID NO: 1, 54 are free of the prior art of record 10. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to M FRANCO G SALVOZA whose telephone number is (571)272-4468. The examiner can normally be reached M-F 8:00 to 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M FRANCO G SALVOZA/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Mar 02, 2024
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788809
CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF
3y 8m to grant Granted Nov 10, 2026
Patent 12781243
MODIFIED IMMUNE EFFECTOR CELL AND PREPARATION METHOD THEREFOR
4y 10m to grant Granted Nov 03, 2026
Patent 12751993
COMPOSITIONS, METHODS AND KITS FOR TREATING COMPLEMENT RELATED DISORDERS
3y 4m to grant Granted Oct 06, 2026
Patent 12735470
ENGINEERED T CELL RECEPTORS AND METHODS OF USE
3y 9m to grant Granted Sep 15, 2026
Patent 12703722
POPTAG PEPTIDE AND USES THEREOF
4y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+30.7%)
Low
PTA Risk
Based on 629 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month